


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
 (Currently amended claims showing deletions by ~~striketrough~~ and additions by underlining)

1 - 31 (canceled)

32 (currently amended): A pharmaceutical composition for the treatment of hyperlipidemia in a patient in need thereof, comprising a therapeutically effective amount of an agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor and a binding affinity (K_i) of less than 5nM for the somatostatin type-5 receptor, wherein said agonist is selected from the group consisting of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH₂; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH₂; and



and wherein said therapeutically effective amount is an amount that is effective for the treatment of hyperlipidemia in said patient.


33 (canceled)

34 (previously presented): A pharmaceutical composition according to claim 32, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i of less than 2 nM for the somatostatin type-5 receptor.

35 (previously presented): A pharmaceutical composition according to claim 32, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i for the type-5 somatostatin receptor that is at least 10 times less than its K_i for the somatostatin type-2 receptor.

36 - 37 (canceled)

38 (currently amended): A pharmaceutical composition for lowering the amount of triacylglycerols in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of an agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor and a binding affinity (K_i) of less than 5nM for the somatostatin type-5 receptor, wherein said agonist is selected from the group consisting of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH₂; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH₂; and



and wherein said therapeutically effective amount is an amount that is effective for lowering the amount of triacylglycerols in the blood of said patient.

39 (canceled)


40 (previously presented): A pharmaceutical composition according to claim 38, wherein said agonist

selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i of less than 2 nM for the somatostatin type-5 receptor.

41 (previously presented): A pharmaceutical composition according to claim 38, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i for the type-5 somatostatin receptor that is at least 10 times less than its K_i for the somatostatin type-2 receptor.

42 - 43 (canceled)

44 (currently amended): A pharmaceutical composition for lowering the amount of glycerol in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of an agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor and a binding affinity (K_i) of less than 5nM for the somatostatin type-5 receptor, wherein said agonist is selected from the group consisting of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH₂; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH₂; and



and wherein said therapeutically effective amount is an amount that is effective for lowering the amount of glycerol in the blood of said patient.

45 (canceled)


46 (previously presented): A pharmaceutical composition according to claim 44, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i of less than 2 nM for the somatostatin type-5 receptor.

47 (previously presented): A pharmaceutical composition according to claim 44, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i for the type-5 somatostatin receptor that is at least 10 times less than its K_i for the somatostatin type-2 receptor.

48 - 49 (canceled)

50 (currently amended): A pharmaceutical composition for lowering the amount of cholesterol in the blood of a patient in need of such lowering, comprising a therapeutically effective amount of an agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor and a binding affinity (K_i) of less than 5nM for the somatostatin type-5 receptor, wherein said agonist is selected from the group consisting of H-Cys-

Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH₂; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH₂; H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH₂; and



and wherein said therapeutically effective amount is an amount that is effective for lowering the amount of cholesterol in the blood of said patient.

51 (canceled)

52 (previously presented): A pharmaceutical composition according to claim 50, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i of less than 2 nM for the somatostatin type-5 receptor.

53 (previously presented): A pharmaceutical composition according to claim 50, wherein said agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor has a K_i for the type-5 somatostatin receptor that is at least 10 times less than its K_i for the somatostatin type-2 receptor.

54 - 55 (canceled)